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The paper gives an overview on the allelic variant of CYP2D6 genotype.  The gene CYP2D6*3 encodes a 
member of the cytochrome P450 super family of enzymes. The cytochrome P450 proteins are 
monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of 
cholesterol, steroids and other lipids. The protein localizes to the endoplasmic reticulum and is known 
to metabolize as many as 20% of commonly prescribed drugs. Its substrates include debrisoquine, an 
adrenergic-blocking drug; sparteine and propafenone, both anti-arrythmic drugs; and amitryptiline, an 
anti-depressant. The emerging application of pharmacogenomics in the clinical trials requires careful 
comparison with the traditional genotypic methodologies particularly in the drug metabolism area. 
 





The Homo sapiens genome is stored on the 23 chromo-
some pairs in which twenty-two of these are autosomal 
chromosome pairs, while the remaining pairs are sex-
determining. The haploid human genome occupies a total 
of just over 3 billion DNA base pairs and has a data size 
of approximately 750 megabytes. The Human Genome 
Project produced a reference sequence of the euchro-
matic human genome, which is used worldwide in 
biomedical sciences and to study the significance of 
genetic polymorphisms in human population. It can be 
defined as the occurrence together in the same popu-
lation of more than one allele or genetic marker at the 
same locus with the least frequent allele or marker 
occurring more frequently than can be accounted for by 
mutation alone. The gene CYP2D6 is highly polymorphic 
in the population and certain alleles result in the poor 
metabolizer phenotype, characterized by a decreased 
ability to metabolize the enzyme's substrates. Polymor- 





Abbreviations: PCR, Polymerase chain reaction; RFLP, 
restriction fragment length polymorphism; SNPs, single 
nucleotide polymorphisms; BBB, blood brain barrier; EM, 
extensive metabolism; PM, poor metabolism. 
with different patterns of susceptibility to the effects of 
carcinogenic substances and drugs and to detect the 
allelic variants of CYP2D6*3 genotype through polyme-
rase chain reaction (PCR) (Steen et al., 1995; Johansson 
et al., 1996). One limitation, however, is the unafford-
ability of some of the current diagnostic methods. PCR is 
an affordable molecular diagnostic technology and is 
already in use in low income regions. The development of 
a strategy for CYP2D6 genotyping covering the most 
commonly described alleles could therefore promote the 
use of these technologies in the developing world. The 
gene is located near two cytochrome P450 pseudogenes 
on the chromosome 22 q13.1. Cytochrome P450 mono-
oxygenases, often referred simply to as CYP enzymes, 
catalyze oxygen insertion into many different kinds of 
substrates, including natural steroids, fatty acids and 
foreign compounds, in a step of their metabolism. The 
enzyme for drug metabolism, toxification as well as 
detoxification of xenobiotic (non-biological) compounds is 
prevalent in the environment (Nebert, 1997; Kohler et al., 
1997). It is expressed in both the gastrointestinal tract and 
hepatic microsomes, and the activity may vary between 
6- and 30-fold among individuals due to genetic and non 
genetic factors such as drug therapy (Griese et al., 1998; 
McElroy et al., 2000; Nei et al., 2001).  The general use 
of CYP2D6 genotyping may be of help to increase the 





al., 2002; Daar et al., 2005). 
 
 
INTRODUCTION TO CYP2D6 GENE 
 
The CYP2D6 gene encodes a member of the cytochrome 
P450 super family of enzymes. The gene is highly 
polymorphic in the population. Cytochrome P450 2D6 
(CYP2D6) is of great importance for frequently identified 
alleles in a given clinical situation, independent variation 
in drug efficacy and toxicity. It has been recognized for 
many decades that individual differences in response to 
pharmacologic treatment, exhibited as drug toxicity or a 
lack of therapeutic effect, are often caused by genetic 
differences that result in altered rates of biotrans-
formation (metabolism). Notable examples include nerve 
damage among individuals homozygous for some 
variants of the N-acetyltransferase 2 gene ("slow 
acetylators") given isoniazid as an antituberculosis therapy, 
haemolytic anaemia among glucose 6-phosphate 
dehydrogenase-deficient patients given aminoquinoline 
antimalarial drugs, and varied rates of biotransformation 
of debrisoquine, an antihypertensive drug, due to genetic 
variation at the CYP2D6 locus. The CYP2D6 is of great 
importance for the metabolism of clinically used drug 
(Lerena et al., 1996; Weber and Myers, 1997; Dahl., 
2002; Berecez et al., 2002; Lerena et al., 2002 and 
Berecez et al., 2003). Still certain alleles result in the poor 
metabolizer phenotype, characterized by a decreased 
ability to metabolize the enzyme's substrates. The detec-
tion of allelic variant of CYP2D6*3 genotype could be 
done through PCR-restriction fragment length poly-
morphism (RFLP) by the property of genetic marker at 
the same locus with the least frequent allele or marker 
occurring more frequently than can be accounted for by 
mutation alone. With the initial completion of the first draft 
of the human genome sequence (Lander et al., 2001; 
Venter et al., 2001), interest has dramatically increased in 
the role of genetics as a determinant of health.  In 
particular, the CYP2D6 allele frequency varies between 
populations and geographical areas (Bradford, 2002). 
Progress in incorporating genetics into public health 
research has been steady over the last several years, 
relying mainly on the tools of genetic and molecular 
epidemiology. The recent abundance of epidemiologic 
research examining associations between polymorphic 
genes that code for enzymes involved in xenobiotic 
biotransformation and disease occasionally generated 
has interesting findings. Much of the impetus for this area 
of research has come from pharmacogenetics, which is 




THE PROCESS OF BIOTRANSFORMATION  
 
The enzymatic alteration of foreign or xenobiotic com-
pounds is conventionally divided into two phases. Phase I 




enzymes modify existing functional groups (e.g., -OH, -
SH) to xenobiotics and are catalyzed primarily by the 
cytochrome P450 enzymes (CYPs). These interme-diates 
are then conjugated with endogenous ligands during 
phase II, increasing the hydrophilic nature of the com-
pound, facilitating excretion (Raunio et al., 1995). Table 1 
shows the reactions and enzymes involved in metabolism 
of xenobiotics. These transporters facilitate the excretion 
of xenobiotics into bile or blood, and thus form what has 
been called phase III biotransformation.  
 
 
THE ROLE OF SINGLE NUCLEOTIDE 
POLYMORPHISM   
 
About 90% of all DNA sequence variations occur as 
single nucleotide polymorphisms (SNPs)--that is, single-
base-pair substitution. SNPs represent a natural genetic 
variability at high density in the human genome. SNPs 
are considered to be the major genetic source to 
phenotypic variability that differentiates individuals within 
a given species. The frequency, stability, and relatively 
even distribution of SNPs in the genome make them 
particularly valuable as genetic markers. Where particular, 
SNP variants are close to a susceptibility gene allele, 
they tend to be inherited together over many generations. 
SNPs may occur in non-coding regions (SNPs) as well as 
in coding regions (cSNPs). There are estimated to be 
three or four SNPs in the average gene and roughly 
120,000 common coding-region SNPs, of which 
approximately 40% are expected to be functional (Cargill 
et al., 1999). Functional polymorphism in XMEs is Point 
mutations in coding regions of genes resulting in amino 
acid substitutions, which may alter catalytic activity, 
enzyme stability, and/or substrate specificity. One of the 
most extensively studied genetic polymorphisms known 
to influence drug metabolism and response is the 
debrisoquine type (CYP2D6) oxidation polymorphism. 
CYP2D6 is the only one functional gene in the CYP2D 
subfamily, present in human genome (Nelson et al., 
1996). The discovery of CYP2D6 polymorphism created 
new interest in the role of pharmacogenetics in clinical 
pharmacology. More than 60 allelic variants have been 
reported for CYP2D6 (Streetman et al., 2000). Of these, 
CYP2D6 mostly affects the activity of the expressed 
protein. CYP2D6 represents 1-5% of the total P450 
(Pelkonen and Breimer, 1994; Shimada et al., 1994; 
Pelkonen et al., 1998), and 7-8 % of the Caucasian 
population are polymorphic (PM) for this enzyme (Heim 
and Meyer, 1992).  
 
 
OVERVIEW ON CYP    
 
Cytochrome P450 is a very large and diverse superfamily 
of hemoproteins found in all domains of life. Cytochrome 
P450  uses  a plethora of both exogenous and endogenous  




Table 1.  Reactions and enzymes involved in metabolism of xenobiotics. 
 
Reaction Enzymes 
Phase 1  
Oxidation  Cytochrome P450, peroxidases, flavin 
Epoxidation 
  
Monooxygenases, monoamine oxidases, alcohol dehydrogenases, aldehyde 
dehydrogenases 
Cytochrome P450  Cytochrome P450, NADPH-cytochrome P450, 
Reduction Reductases, quinone, reductases 
Dealkylation  Cytochrome P450 
Hydrolysis  Carboxyl esterases, amidases 
Dehalogenation Cytochrome P450 
Phase 2  
Conjugation with glucuronic acid  UDP-glucuronyl transferase 
Conjugation with sulphates  Sulphotransferases 
Conjugation with glutathione acetylation  Glutathione S-transferases, N-acetyl transferases 
Conjugation with amino acids  Transferases 
Methylation  Methyl transferases 
Hydralation Epoxide hydrolase 
 
(Source http:// www. Wikipedia.org). 
 
 
    
 
 




compounds as substrates in enzymatic reactions. Usually, 
they form part of multicomponent electron transfer 
chains, called P450-containing systems. The most com-
mon reaction catalysed by cytochrome P450 is a 
monooxygenase reaction. CYP enzymes have been 
identified from all lineages of life, including mammals, 
birds, fish, insects, worms, sea squirts, sea urchins, 
plants, fungi, slime molds, bacteria and archaea. More 
than 7700 distinct CYP sequences are known. The name 
cytochrome P450 is derived from the fact that these are 
colored ('chrome') cellular ('cyto') proteins, with a 
"pigment at 450 nm", so named for the characteristic. 
Soret  peak is formed by absorbance of light at wavelengths 
near 450 nm when the heme iron is reduced (often with 
sodium dithionite) and complexed to carbon monoxide. 
The active site of cytochrome P450 contains a heme iron 
center. The iron is tethered to the P450 protein via a 
thiolate ligand derived from a cysteine residue. This 
cysteine and several flanking residues (RXCXG) are 
highly conserved in known CYPs because of the vast 
variety of reactions catalyzed by CYPs; the activities and 
properties of the many CYPs differ in many aspects and 
its 3D structure is shown in Figure 1. 
 
 
MECHANISM OF CYP450 ENZYME COMPLEX 
 
The P450 catalytic cycle shows the steps involved when 
a substrate binds to the enzyme in the normal state of a 
P450 with the iron in its ferric [Fe3+] state. When the 
substrate binds to the enzyme, the enzyme is reduced to 
the ferrous [Fe2+] state by the addition of an electron from 
NADPH cytochrome P450 reductase. The bound substrate 
facilitates this process. Molecular oxygen binds and 
forms a Fe2+OOH complex with the addition of a proton 
and a second donation of an electron from either NADPH 
cytochrome P450 reductase or cytochrome b5. A second 
proton cleaves the Fe2+OOH complex to form water. An 
unstable [FeO]3+ complex donates its oxygen to the 
substrate. The oxidised substrate is released and the 
enzyme returns to its initial state. The active site of 
cytochrome P450 contains a heme iron center. The iron 
is tethered to the P450 protein via a thiolate ligand 
derived from acysteine residue. This cysteine and several 
flanking residues are highly conserved in known CYPs 
enzyme complex (Daly et al., 1996). 








Polymorphism Function of 
polymorphic allele 
Relation of polymorphism to the disease 









Tumors of liver, colon and urinary bladder. 
 









Tumors of nasopharynx, effect on the metabolism 
of medicaments. 




THE ROLE OF CYP ENZYME COMPLEX 
 
Cytochrome P450 mono-oxygenases (hydroxylases), 
often referred simply to as CYP enzymes, catalyze 
oxygen insertion into many different kinds of substrates, 
including natural steroids, fatty acids and foreign 
compounds, in a step of their metabolism. They serve as 
the enzymes for drug metabolism, toxification as well as 
detoxification of xenobiotic (non-biological) compounds 
prevalent in the environment. Several classes of xeno-
biotic compounds thus elicit characteristic biological 
effects in vivo due often to intermediate metabolites. 
These enzymes are expressed in both the gastro-intestinal 
tract and hepatic microsomes, and the activity may vary 
between 6- and 30-fold among individuals due to genetic 
and non genetic factors such as drug therapy (Pelkonen 
et al., 1994). Humans have 57 genes and more than 59 
pseudogenes are divided among 18 families of cytochrome 
P450 genes and 43 subfamilies (Daly et al., 1996). 
 
 
SIGNIFICANCE OF CYTOCHROME P450 IN HUMANS  
 
Human CYPs are primarily membrane-associated proteins, 
located either in the inner membrane of mitochondria or 
in the endoplasmic reticulum of cells. CYPs metabolise 
thousands of endogenous and exogenous compounds. 
Most CYPs can metabolize multiple substrates, and 
many can catalyze multiple reactions, which accounts for 
their central importance in metabolizing the extremely 
large number of endogenous and exogenous molecules. 
In the liver, these substrates include drugs and toxic 
compounds as well as metabolic products such as 
bilirubin (a breakdown product of hemoglobin). Cyto-
chrome P450 enzymes are present in many other tissues 
of the body including the mucosa of the gastrointestinal 
tract, and play important roles in hormone synthesis and 
breakdown cholesterol synthesis, and vitamin D meta-
bolism. Hepatic cytochromes P450 are the most widely 
studied of the P450 enzymes and the characteristics in 
relation to genetic polymorphism are shown in Table 2. 
Cytochrome  P450s  are  also  present  in the blood brain 
barrier (BBB) in concentrations similar to those found in 
the liver. They strengthen the division between the blood 
and brain tissue by metabolising toxic compounds which 
may somehow cross the BBB. The Human Genome 
Project has identified more than 63 human genes (57 full 
genes and 5 pseudogenes) coding for the various 
cytochrome P450 enzymes (Heim and Meyer, 1992). 
 
 
VARIOUS ASPECTS OF CYP2D6   
 
Cytochrome P450 2D6 (CYP2D6), a member of the 
cytochrome P450 mixed-function oxidase system, is one 
of the most important enzymes involved in the meta-
bolism of xenobiotics in the body. Its 3D structure is 
shown in Figure 2. Whilst CYP2D6 is involved in the 
oxidation of a wide range of substrates of all the CYPs, 
there is considerable variability in its expression in the 
liver. The gene is located near two cytochrome P450 
pseudogenes on chromosome 22q13.1. Alternatively, 
spliced transcript variants encoding different isoforms 
have been found for this gene.                                       
CYP2D6 shows the largest phenotypical variability 
amongst the CYPs, largely due to genetic polymorphism. 
The genotype accounts for the normal, reduced and non-
existent CYP2D6 function in subjects. More than 50 
human CYP Isoenzymes have been identified (Mc Leod 
and Danielson, 2002).  The genetic basis for extensive 
and poor metaboliser variability is the CYP2D6 allele, 
located on chromosome 22 (Eichelbaum and Gross, 
1987). Subjects who possess certain allelic variants will 
show normal, decreased or no CYP2D6 function depen-
ding on the allele. In CYP2D6, genetic polymorphism has 
been linked to three classes of phenotypes based on the 
extent of drug metabolism. Extensive metabolism (EM) of 
a drug is characteristic of the normal population; poor 
metabolism (PM) is associated with accumulation of 
specific drug substrates and is typically an autosomal 
recessive trait requiring mutation and/or deletion of both 
alleles for phenotypic expression; and ultra extensive 
metabolism (UEM) results in increased drug metabolism 
and  is  an  autosomal  dominant  trait  arising  from  gene 




















amplification (Yachna, 2009).  
Dextromethorphan (the cough suppressant part of 
Dimetapp DM) can be used as a "probe" to assess whether 
an individual is an extensive vs. normal vs. poor 
metabolizer with regards to CYP2D6. Notably, some 
drugs (e.g. quinidine) can change an extensive metabolizer 
into a poor metabolizer of dextromethorphan. CYP2D6 
are bimodally distributed in the population allowing 
classification of individuals as either extensive (EMs) or 
poor (PMs) metabolizers. A patient's CYP2D6 phenotype 
is often clinically determined via the admini-stration of 
debrisoquine (a selective CYP2D6 substrate) and subse-
quent plasma concentration assay of the debrisoquine 
metabolite (4-hydroxydebrisoquine).   
Debrisoquine is a drug used for treating hypertension, 
and a wide variation has been observed in the hypoten-
sive response. The P450-debrisoquine hydroxylase 
polymorphism in humans is one of the best-studied 
enzyme deficiencies, and it has been variously linked 
with different types of cancer, including those of the lung, 
bladder and breast. CYP2D6 converts debrisoquine 
(active) into 4-hydroxydebrisoquine (inactive). This 
polymorphism is characterized by the inability of certain 
individuals to metabolize specific drugs (e.g. debriso-
quine, sparteine, and bufuralol); affected individuals, 
termed poor metabolizers (PMs), are known to be 
deficient in the minor liver enzyme P450-CYP2D6 which 
is responsible for the metabolism of these compounds. 





manner in 5-10% of the Caucasian population and is now 
associated with the inefficient metabolism of over 30 




CYP2D6 AND CANCER SUSCEPTIBILITY  
 
An association was observed between CYP2D6 gene 
and lung cancer (Caporaso et al., 1990) and oral cancer 
(Worrall et al., 1998). Bouchardy et al. (1996) evaluated 
CYP2D6 activity, determined by in vivo metabolic rate of 
dextromethorphan, in 128 cases of lung cancer and 157 
controls. Increased CYP2D6 activity (EM phenotype) has 
been related to some malignant processes, like bladder 
cancer (Anwar et al., 1996). The data suggested that the 
increased metabolism of one or more agents in the diet 
or other environmental agents, mediated by CYP2D6, 
forms reactive intermediaries that influence the initiation 
or promotion of cancer in various tissues (Nebert, 1997). 
Meanwhile, reduced CYP2D6 activity (PM phenotype) 
has been related to greater risk of Parkinson’s disease 
(Smith et al., 1992), leukemia and oral cancer (Worrall et 
al., 1998). The distinction was not clear between the EM 
and PM phenotypes and susceptibility to cancer. This 
could be explained by the fact that PM individuals, much 
less exposed than EMs to the metabolites of carcinogenic-
genotoxic drugs, must be exposed longer to the toxic 
effects of non-metabolized drugs and numerous other 
factors still not identified. It was known that the toxic 
effects can contribute to carcinogenesis, for example, 
through a necrogenic response followed by compen-
satory increased cell division (Butterworth et al., 1992). It 
has been found that polymorphism at loci that encode 
carcinogen-metabolizing enzyme such as cytochrome 
P450 catalyzing the detoxification of carcinogens may 
determine susceptibility to cervical cancer. Some studies 
showed no-association between CYP2D6 and cancer 
risks. London et al. (1997) found that the CYP2D6 genetic 
polymorphism is not the strong risk factor for lung cancer. 
Smith et al. (1992) and Goetz et al. (2007) stated that 




DRUG METABOLISM IN CYP2D6  
 
The basic purpose of drug metabolism in the body is to 
make drugs more water soluble and thus more readily 
excreted in the urine or bile. One common way of 
metabolizing drugs involves the alteration of functional 
groups on the parent molecule (e.g., oxidation) that is, 
the cytochrome P450 enzymes e.g., CYP2D6. Drug 
interactions involving the cytochrome P450 isoforms 
generally result from one of two processes, enzyme 
inhibition or enzyme induction. Enzyme inhibition usually 
involves competition with another drug for the enzyme 





dose of the inhibitor, and onset and offset of inhibition 
correlate with the half-lives of the drugs involved. Enzyme 
induction occurs when a drug stimulates the synthesis of 
more enzyme protein, enhancing the enzyme's metaboli-
zing capacity (Shimada et al., 1994; Douglas et al., 1994). 
 
 
CYP2D6 AND DRUG INTERACTIONS  
 
Due to the high polymorphic character of CYP2D6, this 
enzyme is also the site of a number of drug interactions 
in vivo, which are of clinical significance. Substrates with 
a high affinity for the enzyme bind strongly to it and inhibit 
the metabolism of other compounds which have lower 
affinity. Consequently, drug interactions occur in extensive 
as well as poor metabolisers. By using this knowledge, 
pharmacokinetic interactions can be anticipated as 
follows: If drug A affects P450 enzyme X and if P450 
enzyme X metabolises drugs B, C and D, then drug A 
should affect the metabolism of drug B, C and D. This 
type of knowledge is also being used to decide which 
drugs to develop, because the inhibition of P450 enzyme 
is generally not the goal of treatment. The interaction of 
two substrates for CYP2D6 can result in a number of 
clinical responses. The first pass metabolism of the 
substrate may be inhibited or the rate of elimination may 
be prolonged such that higher plasma concentration and 
associated pharmaco-dynamic responses may occur. 
Inhibition of metabolism by CYP2D6 can also lead to a 
lack of therapeutic response when the pharmacological 
action is dependent on the active metabolite. Since 
CYP2D6 is not inducible by enzyme inducing drugs, drug 
interactions due to enzyme induction are very unlikely to 
occur (Broly et al., 1995; Johansson et al., 1996). 
 
 
IMPLICATION FOR DRUG DEVELOPMENT  
 
The knowledge gained about these polymorphism studies 
should be incorporated into drug development at an early 
stage to determine whether or not the drug is metabolized 
by CYP2D6 and hence subject to genetic polymorphism. 
Since phase-1 clinical trials are carried out at a rather 
later time during drug development, usually five to seven 
years after the initial discovery, a strategy, which allows 
for an earlier recognition of this phenomenon, would be 
desirable. Dosing regimens are normally established 
during the phase-1 evaluation of drugs and are based on 
studies of relatively small number of subjects. 
However, with respect to oxidation phenotype, the 
subjects may not be representative of the general popu-
lation. If it were possible to predict that the metabolism of 
a drug co-segregates with a known polymorphism at the 
preclinical stage, the decision on whether or not to 
pursue development of the drug would be facilitated. 
Several in vitro approaches have been developed which 
allow a prediction to be made during preclinical testing if 
the  metabolism  of  a  new  drug   is   subject   to  genetic  




polymorphism. Inhibitory monoclonal antibodies are 
available which determine cytochrome P450 substrate 
and product specificity. It is obviously also prudent to 
exclude potentially susceptible individuals from phase-1 
dose escalation trials. This can prevent PM healthy 
subjects or patients being exposed to additional risk of 
toxicity during phase-1 and 2 developments. There is 
currently great interest in the pharmaceutical industries in 
pharmacogenetics and an increasing number of compa-
nies are genotyping their clinical trial populations. 
Moreover, the knowledge of genetic variability in drug 
response is becoming an increasingly important component 
of the drug registration process (Shimada et al., 1994; 
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